Legal Representation
Attorney
Anthony P. Venturino
USPTO Deadlines
Next Deadline
9 days remaining
Statement of Use Due - Extension 5 Granted
Due Date
July 19, 2025
Application History
45 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 28, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 28, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Mar 28, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Dec 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 12, 2024 | EXT5 | S | SOU EXTENSION 5 FILED |
| Jun 14, 2024 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jun 14, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Jun 14, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jun 14, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jan 18, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jan 16, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Jan 16, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
| Jan 16, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 31, 2023 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Oct 31, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Oct 31, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 31, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 20, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 18, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Jul 18, 2023 | EXT2 | S | SOU EXTENSION 2 FILED |
| Jul 18, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 17, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 17, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 17, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Feb 21, 2023 | DOCK | D | ASSIGNED TO EXAMINER |
| Jan 20, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jan 18, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Jan 18, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
| Jan 18, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 19, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| May 25, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| May 24, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| May 24, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 4, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Apr 18, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Apr 11, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 18, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Feb 17, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Feb 17, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Aug 17, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 17, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Aug 17, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 12, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| May 6, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 6, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 035
Marketing for diagnostic, therapeutic, and prophylactic products, namely, pharmaceuticals in the field of the management of rare disease
Class 041
Educational resource in the nature of non-downloadable electronic publications in the nature of books, magazines, newsletters, brochures, reports, case studies, journals, and instructional and teaching material in the field of medicine and pharmaceuticals; Educational services, namely, conducting classes, seminars, conferences, workshops in the field of medicine and pharmaceuticals, and distribution of training material in connection therewith
Class 044
Providing a website featuring information in the field of the diagnosis and treatment of Cushing's Disease; Educational information regarding the diagnosis and treatment of Cushing's Disease
Classification
International Classes
035
041
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CUSHING'S DISEASE"